Latest white paper

How do I save >12 months of drug development time? Download the Tufts CSDD white paper

Tufts US Seminar Series

Join our complimentary lunch seminar series taking place in five US locations.

Title: Assessing the Financial Impact of Translational Pharmaceutics - A Platform for Accelerating Drug Development

Seminar Overview: The drug development process has been demonstrated to be costly and lengthy, with significant rates of molecule attrition and development risk. Despite long-standing efforts by drug developers to operate more efficiently, traditional drug development programs have become costlier.  To inform drug developers of the time savings and potential financial impacts of alternative drug development processes and outsourcing models, the Tufts CSDD conducted a study comparing the traditional drug development paradigm with Quotient Sciences’ signature drug development platform, referred to as Translational Pharmaceutics®. Translational Pharmaceutics is widely used by pharmaceutical and biotech companies to accelerate product development. Key applications of Translational Pharmaceutics include the transition of molecules from First in Human (FIH) to Proof of Concept (POC), and in the development and optimization of clinical formulations. This presentation will summarize the key findings of the Tufts CSDD research, which reported a mean reduction in development cycle times of over 12 months and overall financial gains of at least $100m per approved drug.

Locations & Dates:

San Diego, CA - Monday, March 16th, 2020 Learn more 

San Francisco, CA - Thursday, March 19th, 2020  Learn more 

New York City, NY at DCAT - Tuesday, March 24th, 2020 Learn more

Cambridge, MA - Thursday, March 26th, 2020 Learn more

Garnet Valley, PA - Thursday, April 2nd, 2020 Learn more

Space is limited, so save your spot today!

Drug product development

Take a look at our expert resources

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.